Literature DB >> 22362332

Cytoskeletal proteins in the cerebrospinal fluid as biomarker of multiple sclerosis.

Roberto Madeddu1, Cristiano Farace, Paola Tolu, Giuliana Solinas, Yolande Asara, Maria Alessandra Sotgiu, Lucia Gemma Delogu, Jose Carlos Prados, Stefano Sotgiu, Andrea Montella.   

Abstract

The axonal cytoskeleton is a finely organized system, essential for maintaining the integrity of the axon. Axonal degeneration is implicated in the pathogenesis of unremitting disability of multiple sclerosis (MS). Purpose of this study is to evaluate levels of cytoskeletal proteins such as neurofilament light protein (NFL), glial fibrillary acidic protein (GFAP), and β-tubulin (β-Tub) isoforms II and III in the cerebrospinal fluid (CSF) of MS patients and their correlation with MS clinical indices. CSF levels of cytoskeletal proteins were determined in 51 patients: 33 with MS and 18 with other neurological diseases (OND). NFL, GFAP and β-Tub II proteins were significantly higher (p < 0.0001) in MS than in OND group; no significant difference (p > 0.05) was found between MS and OND with regard to β-Tub III. Interestingly, levels of β-Tub III and NFL were higher in progressive than in remitting MS forms; on the contrary, higher levels of β-Tub II and GFAP were found in remitting MS forms. However, with the exception of β-Tub III, all proteins tend to decrease their CSF levels concomitantly with the increasing disability (EDSS) score. Overall, our results might indicate β-Tub II as a potential candidate for diagnostic and β-Tub III as a possible prognostic biomarker of MS. Therefore, further analyses are legitimated and desirable.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22362332     DOI: 10.1007/s10072-012-0974-4

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  43 in total

1.  Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab.

Authors:  Martin Gunnarsson; Clas Malmeström; Markus Axelsson; Peter Sundström; Charlotte Dahle; Magnus Vrethem; Tomas Olsson; Fredrik Piehl; Niklas Norgren; Lars Rosengren; Anders Svenningsson; Jan Lycke
Journal:  Ann Neurol       Date:  2010-12-08       Impact factor: 10.422

2.  Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination.

Authors:  C Lucchinetti; W Brück; J Parisi; B Scheithauer; M Rodriguez; H Lassmann
Journal:  Ann Neurol       Date:  2000-06       Impact factor: 10.422

3.  Identification of conserved isotype-defining variable region sequences for four vertebrate beta tubulin polypeptide classes.

Authors:  K F Sullivan; D W Cleveland
Journal:  Proc Natl Acad Sci U S A       Date:  1986-06       Impact factor: 11.205

4.  Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis.

Authors:  M Axelsson; C Malmeström; S Nilsson; S Haghighi; L Rosengren; J Lycke
Journal:  J Neurol       Date:  2011-01-01       Impact factor: 4.849

5.  Heightened intrathecal release of axonal cytoskeletal proteins in multiple sclerosis is associated with progressive disease and clinical disability.

Authors:  Y K Semra; O A Seidi; M K Sharief
Journal:  J Neuroimmunol       Date:  2002-01       Impact factor: 3.478

6.  Glial fibrillary acidic protein in CSF of multiple sclerosis patients: relation to neurological deficit.

Authors:  L E Rosengren; J Lycke; O Andersen
Journal:  J Neurol Sci       Date:  1995-11       Impact factor: 3.181

Review 7.  Development of biomarkers in multiple sclerosis.

Authors:  Bibiana Bielekova; Roland Martin
Journal:  Brain       Date:  2004-06-04       Impact factor: 13.501

8.  Cerebrospinal fluid markers in MS patients and their healthy siblings.

Authors:  S Haghighi; O Andersen; A Odén; L Rosengren
Journal:  Acta Neurol Scand       Date:  2004-02       Impact factor: 3.209

9.  Differential distribution of beta-tubulin isotypes in cerebellum.

Authors:  R D Burgoyne; M A Cambray-Deakin; S A Lewis; S Sarkar; N J Cowan
Journal:  EMBO J       Date:  1988-08       Impact factor: 11.598

10.  Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis.

Authors:  W I McDonald; A Compston; G Edan; D Goodkin; H P Hartung; F D Lublin; H F McFarland; D W Paty; C H Polman; S C Reingold; M Sandberg-Wollheim; W Sibley; A Thompson; S van den Noort; B Y Weinshenker; J S Wolinsky
Journal:  Ann Neurol       Date:  2001-07       Impact factor: 10.422

View more
  14 in total

Review 1.  Secondary Progressive Multiple Sclerosis: Definition and Measurement.

Authors:  Domenico Plantone; Floriana De Angelis; Anisha Doshi; Jeremy Chataway
Journal:  CNS Drugs       Date:  2016-06       Impact factor: 5.749

2.  Total protein is an effective loading control for cerebrospinal fluid western blots.

Authors:  Mahlon A Collins; Jiyan An; Danielle Peller; Robert Bowser
Journal:  J Neurosci Methods       Date:  2015-05-22       Impact factor: 2.390

Review 3.  Upcoming candidate cerebrospinal fluid biomarkers of Alzheimer's disease.

Authors:  Anne M Fagan; Richard J Perrin
Journal:  Biomark Med       Date:  2012-08       Impact factor: 2.851

Review 4.  Treatment trials in progressive MS--current challenges and future directions.

Authors:  Marcus W Koch; Gary Cutter; Peter K Stys; V Wee Yong; Luanne M Metz
Journal:  Nat Rev Neurol       Date:  2013-07-30       Impact factor: 42.937

Review 5.  Blood GFAP as an emerging biomarker in brain and spinal cord disorders.

Authors:  Ahmed Abdelhak; Matteo Foschi; Samir Abu-Rumeileh; John K Yue; Lucio D'Anna; Andre Huss; Patrick Oeckl; Albert C Ludolph; Jens Kuhle; Axel Petzold; Geoffrey T Manley; Ari J Green; Markus Otto; Hayrettin Tumani
Journal:  Nat Rev Neurol       Date:  2022-02-03       Impact factor: 44.711

Review 6.  Axonal degeneration in multiple sclerosis: can we predict and prevent permanent disability?

Authors:  Jae Young Lee; Kasra Taghian; Steven Petratos
Journal:  Acta Neuropathol Commun       Date:  2014-08-27       Impact factor: 7.801

Review 7.  Neurofilament light chain as a biological marker for multiple sclerosis: a meta-analysis study.

Authors:  Laisheng Cai; Jingwei Huang
Journal:  Neuropsychiatr Dis Treat       Date:  2018-09-03       Impact factor: 2.570

Review 8.  Brain-Specific Cytoskeletal Damage Markers in Cerebrospinal Fluid: Is There a Common Pattern between Amyotrophic Lateral Sclerosis and Primary Progressive Multiple Sclerosis?

Authors:  Ahmed Abdelhak; Andreas Junker; Johannes Brettschneider; Jan Kassubek; Albert C Ludolph; Markus Otto; Hayrettin Tumani
Journal:  Int J Mol Sci       Date:  2015-07-31       Impact factor: 5.923

9.  Cerebrospinal fluid biomarkers for Alzheimer disease and subcortical axonal damage in 5,542 clinical samples.

Authors:  Tobias Skillbäck; Henrik Zetterberg; Kaj Blennow; Niklas Mattsson
Journal:  Alzheimers Res Ther       Date:  2013-10-14       Impact factor: 6.982

10.  Rapid, deep and precise profiling of the plasma proteome with multi-nanoparticle protein corona.

Authors:  John E Blume; William C Manning; Gregory Troiano; Daniel Hornburg; Michael Figa; Lyndal Hesterberg; Theodore L Platt; Xiaoyan Zhao; Rea A Cuaresma; Patrick A Everley; Marwin Ko; Hope Liou; Max Mahoney; Shadi Ferdosi; Eltaher M Elgierari; Craig Stolarczyk; Behzad Tangeysh; Hongwei Xia; Ryan Benz; Asim Siddiqui; Steven A Carr; Philip Ma; Robert Langer; Vivek Farias; Omid C Farokhzad
Journal:  Nat Commun       Date:  2020-07-22       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.